Previous close | 53.06 |
Open | 53.06 |
Bid | 33.30 |
Ask | 40.50 |
Strike | 1,100.00 |
Expiry date | 2025-01-17 |
Day's range | 53.06 - 53.06 |
Contract range | N/A |
Volume | |
Open interest | 5 |
Regeneron (REGN) and Lexicon (LXRX) are in the spotlight following drug approval and regulatory update, respectively.
REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).
HRMY vs. REGN: Which Stock Is the Better Value Option?